Excorp Medical

739 Kasota Avenue Minneapolis, MN 55414, USA Phone: +1 612-331-9009 www.excorp.com Contact E-Mail

Company Description

At Excorp Medical, Inc., we have developed a system for the temporary metabolic support of patients in acute liver failure in an 8-year collaboration with the leading University in liver transplantation and tissue engineering. We have completed laboratory, preclinical and initial FDA-authorized Phase I/II human clinical studies and have established the proof of principle for the technology along with proprietary protection and sufficient clinical and technical information to enter the final stages of development and product launch.

Products

• Bioartificial Liver System
  
  Our Bioartificial Liver System comprises an extracorporeal (outside the body) process for continuously withdrawing a patient's whole venous blood, maintaining temperature, oxygenating to arterial levels, adjusting pH to 7.2, and perfusing a hollow fiber bioreactor charged with primary porcine hepatocytes before returning the blood to the patient. Porcine hepatocytes are obtained from qualified animals produced in a high health status herd. Approximately 100 grams of hepatocytes are infused into the hollow fiber cartridge. Viability, oxygen consumption and other parameters are monitored to establish potency of each hepatocyte preparation and the resulting Bioreactor. The hollow fiber membrane, which serves as an immunoisolation barrier between the two species, is 1.7 m2 in surface area and has a nominal molecular weight cutoff of 100 kD. During clinical hemoperfusion, blood flow rates are maintained at 150 to 250 mL/min with a therapeutic procedure designed to last for 12 hours. The instrument console provides control of the process, detecting potentially hazardous conditions and alerting the operator to appropriate corrective actions.